Allogene Therapeutics, Inc.
ALLONASDAQHealthcare● Active
$1.85
$-0.03(-1.60%)
Market Cap$451158381
P/E Ratio—
52W High$4.46
52W Low$0.98
Allogene Therapeutics, Inc. (ALLO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ALLO · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.18
Est. -$0.19 · +5.3%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▲ Beat EPS🔥 11-Quarter EPS Beat Streak
ALLO reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.16 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 13, 2026 | -$0.19 | -$0.18 | +5.3% | — | $0.00B | — |
| ▲ Q1 FY2026 | Mar 12, 2026 | -$0.25 | -$0.17 | +32.0% | — | $0.00B | — |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.23 | -$0.19 | +17.4% | — | $0.00B | — |
| ▲ Q3 FY2025 | Aug 13, 2025 | -$0.28 | -$0.23 | +17.9% | — | — | — |
| — Q2 FY2025 | May 13, 2025 | -$0.28 | -$0.28 | +0.0% | — | $0.00B | — |
| ▲ Q1 FY2025 | Mar 13, 2025 | -$0.34 | -$0.28 | +17.6% | $0.00B | $0.00B | +83.3% |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.34 | -$0.27 | +20.6% | — | $0.00B | — |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.16
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Beat
EPS Actual
-$0.18
EPS Est.
-$0.19
EPS Surpr.
+5.3%
Revenue
—
Q1 FY2026
Mar 12, 2026Beat
EPS Actual
-$0.17
EPS Est.
-$0.25
EPS Surpr.
+32.0%
Revenue
—
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.19
EPS Est.
-$0.23
EPS Surpr.
+17.4%
Revenue
—
Q3 FY2025
Aug 13, 2025Beat
EPS Actual
-$0.23
EPS Est.
-$0.28
EPS Surpr.
+17.9%
Revenue
—
Q2 FY2025
May 13, 2025
EPS Actual
-$0.28
EPS Est.
-$0.28
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2025
Mar 13, 2025Beat
EPS Actual
-$0.28
EPS Est.
-$0.34
EPS Surpr.
+17.6%
Revenue
$0.00B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.27
EPS Est.
-$0.34
EPS Surpr.
+20.6%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.23 | $-0.23 | $-0.23 | 2 |
| Q3 FY2027 | $-0.20 | $-0.20 | $-0.20 | 2 |
| Q2 FY2027 | $-0.20 | $-0.20 | $-0.20 | 2 |
| Q1 FY2027 | $-0.19 | $-0.19 | $-0.19 | 2 |
| Q4 FY2026 | $-0.19 | $-0.19 | $-0.19 | 4 |
| Q3 FY2026 | $-0.22 | $-0.18 | $-0.14 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 5 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 5 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 5 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 5 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 5 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 10 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 13, 2026 | +5.3% | $2.30 | $2.33 | +1.30% |
| ▲ Q1 FY2026 | Mar 12, 2026 | +32.0% | $2.63 | $2.47 | -6.08% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +17.4% | $1.11 | $1.05 | -5.41% |
| ▲ Q3 FY2025 | Aug 13, 2025 | +17.9% | $1.03 | $1.04 | +0.97% |
| ▲ Q2 FY2025 | May 13, 2025 | +0.0% | $1.17 | $1.13 | -3.42% |
| ▲ Q1 FY2025 | Mar 13, 2025 | +17.6% | $2.06 | $1.89 | -8.25% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +20.6% | $3.22 | $3.19 | -0.93% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +8.6% | $2.55 | $2.47 | -3.14% |
Q2 FY2026+1.30%
Report Date
May 13, 2026
EPS Beat/Miss
+5.3%
Price Before
$2.30
Price After
$2.33
Q1 FY2026-6.08%
Report Date
Mar 12, 2026
EPS Beat/Miss
+32.0%
Price Before
$2.63
Price After
$2.47
Q4 FY2025-5.41%
Report Date
Nov 6, 2025
EPS Beat/Miss
+17.4%
Price Before
$1.11
Price After
$1.05
Q3 FY2025+0.97%
Report Date
Aug 13, 2025
EPS Beat/Miss
+17.9%
Price Before
$1.03
Price After
$1.04
Q2 FY2025-3.42%
Report Date
May 13, 2025
EPS Beat/Miss
+0.0%
Price Before
$1.17
Price After
$1.13
Q1 FY2025-8.25%
Report Date
Mar 13, 2025
EPS Beat/Miss
+17.6%
Price Before
$2.06
Price After
$1.89
Q4 FY2024-0.93%
Report Date
Nov 7, 2024
EPS Beat/Miss
+20.6%
Price Before
$3.22
Price After
$3.19
Q3 FY2024-3.14%
Report Date
Aug 7, 2024
EPS Beat/Miss
+8.6%
Price Before
$2.55
Price After
$2.47
Avg Beat Reaction-3.12%
Beat Rate8 / 8 quarters
Largest Move-8.25% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ALLO ends December
Allogene Therapeutics, Inc. (ALLO) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.18 — beating the analyst consensus of $-0.19 by +5.3%. ALLO has beaten EPS estimates for 11 consecutive quarters. The next ALLO earnings date is expected around September 1, 2026.
Each quarter, investors track ALLO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ALLO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ALLO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ALLO earnings · 5 questionsAllogene Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. ALLO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ALLO historically reports after market close (AMC).
ALLO earnings datewhen is ALLO earningsALLO next earnings datewhen does ALLO report earningsALLO earnings calendar
▸ Source: FMP · Allogene Therapeutics, Inc. SEC filings · US GAAP · Allogene Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026